CPI SALUD. Diagnosis and precision treatment in infectious diseases and cancer. ASURANT Challenge

Antimicrobial resistance (AMR) is a serious threat for the public health globally. Deaths and economic losses caused by AMR are increasing at an alarming rate and forecasts suggest AMR could lead to up to 10 million deaths in the next 25 years, and economic losses that would exceed $100 trillion by 2050. Traditional diagnostic methods, regrettably, lack the speed necessary to assist healthcare professionals in promptly determining the most effective treatment for patients, thereby exacerbating their prognosis and recovery.

To confront this challenge, we are actively engaged in designing, developing, and validating an innovative molecular diagnostic solution. This solution combines direct nucleic acid extraction from the sample with qPCR amplification and detection of the main genes responsible for AMR.

The initiative falls under the umbrella of the ASURANT Challenge, a pre-commercial public purchase supported by the Andalusian Health Service and co-funded by the European Regional Development Fund (ERDF).



1.140.000 €

Execution period

12/2020 – 06/2022